BioNTech SE (BNTX) EPS (Weighted Average and Diluted) (2023 - 2024)
BioNTech SE (BNTX) posted EPS (Weighted Average and Diluted) of $191564.2 for Q4 2024, up 30.06% on a QoQ basis from $147284.0 in Q3 2024, and down 15.52% year-over-year from $226762.4 in Q1 2024.
BioNTech SE (BNTX) has 2 years of EPS (Weighted Average and Diluted) data on file, last reported at $191564.2 in Q4 2024.
- In Q4 2024, EPS (Weighted Average and Diluted) fell 15.52% year-over-year to $191564.2; the TTM figure through Dec 2024 stood at $191564.2 (down 15.52% YoY), while the FY2024 annual figure was -$2.96, down 171.83% from the prior year.
- EPS (Weighted Average and Diluted) rose to $191564.2 in Q4 2024, from $147284.0 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $226762.4 in Q4 2023 and bottomed at $82783.5 in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | BioNTech SE | 27.66 Bn | 7.53 Bn | 668.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 144,972.07 |
| Sep 30, 2024 | 244,567.90 |
| Dec 31, 2023 | 226,762.40 |
| Sep 30, 2023 | 151,649.48 |